Latest / Community Health Media
Drs. Amy Krie, Mabel Mardones, & Anne O'Dea - HER2+ Metastatic Breast Cancer: Is DB09 Leading Towards A New First-Line Standard Of Care?
Recorded live at ASCO 2025, Amy Krie, Mabel Mardones, and Anne O'Dea break down the data that could redefine first-line treatment for HER2-positive metastatic breast cancer.
From the legacy of CLEOPATRA to the stunning DB09 results showing median PFS exceeding 40 months, this expert roundtable explores what this shift means in real-world practice.
They tackle patient selection, CNS metastases, toxicity management, dose reductions, and how using the most effective drug first is what is most ethically imperative.
🎧 A must-watch discussion on efficacy, quality of life, and how clinicians should…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.